Bioneb receives £220m investment commitment from Gem Group

Bioneb will use the funds to support the ongoing research and development activities for its FDA-approved ultrasonic vibrating mesh drug delivery devices, medical formulations, and clinical trials. Credit: Darko Stojanovic / Pixabay.